Pegaptanib sodium for ocular vascular disease

Indian Journal of Ophthalmology

Volumn 55, Issue 6, 2007, Pages 427-430

  Shukla, Dhananjay ^a   Namperumalsamy, Perumalsamy ^b   Goldbaum, Mauro ^c   Cunningham Jr , Emmett T ^d,e,f  

^a ARAVIND EYE HOSPITAL   (India)

^b ARAVIND EYE CARE SYSTEM   (India)

^c OSI PHARMACEUTICALS INC   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NONE   (United States)

Author keywords

Age related macular degeneration; Aptamer; Diabetic macular edema; Pegaptanib; Vascular endothelial growth factor

Indexed keywords

EID: 35548941813     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.36476     Document Type: Article

References (29)

1. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611.
2. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino add sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990;50:1774-8.
3. Ng E W, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32.
4. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
5. Cunningham ET Jr, Adamis AP, Goldbaum M. Macugen® (pegaptanib sodium) for the treatment of ocular vascular disease. Expert Rev Ophtltalmol (In press).
6. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, et al. Vegf164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-9.
7. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, et al. Vegfl64 is pro-inflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-62.
8. Ng E, Nishijima K, Robinson GS, Adamis AP, Shima DT. VEGF has both direct and indirect neuroprotective effects in ischemic retina. Invest Ophthalmol Vis Sci 2006;47:4829.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
10. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508-21.
11. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Enhanced efficacy assodated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina 2005;25:815-27.
12. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, et al. Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.
13. Suner IJ. Safety of pegaptanib sodium in age-related macular degeneration (AMD): 3-year results of the VISION trial. Poster presented at: The Annual Meeting of the American Academy of Ophthalmology; November 11-14, 2006; Las Vegas, Nev. Poster 715.
14. Apte RS; for the Macugen AMD Study Group. One-year systemic safety and pharmacokinetics of pegaptanib in patients with neovascular age-related macular degeneration (AMD). Paper presented at: The Annual Meeting of the American Academy of Ophthalmology; November 11-14 2006; Las Vegas, Nev. Poster 721.
15. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-57.
16. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8.
17. Gonzalez VH, Vann VR, Banda RM. Selective VEGF Inhibition: Effectiveness in modifying the progression of proliferative diabetic retinopathy (PDR). Poster presented at: The Annual Meeting of the American Academy of Ophthalmology; November 11-14, 2006; Las Vegas, Nev. Poster 309.
18. Boyd SR, Zachary I, Chakravarthy U, Alien GJ, Wisdom GB, Cree IA, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50.
19. Data on file, (OSI) Eyetech, Inc: New York.
20. rd; for the Pegaptanib in Retinal Central Vein Occlusion Study Group. Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion (CRVO). Poster presented at: The Annual Meeting of the American Academy of Ophthalmology; November 11-14, 2006; Las Vegas, Nev. Poster 370.
21. Filippopoulos T, Ducharme JF, Lowenstein JI, Krzystolik MG. Antiangiogenic agents as an adjunctive treatment for complicated neovascular glaucoma. Invest Ophthalmol Vis Sci 2006;47:4476.
22. Trese MT, Capone A Jr, Drenser K. Macugen in retinopathy of prematurity. Invest Ophthalmol Vis Sci 2006;47:2330.
23. Drenser KA. Macugen therapy for the treatment of familial exudative vitreoretinopathy. Paper presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology; April 30-May 4, 2006; Ft. Lauderdale, Fla.
24. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006;37:446-54.
25. Tolentino MJ, Misch DM, Gerger AS. Avastin enhancement and Macugen maintenance therapy for exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:5912.
26. Genentech, Inc. Health-care provider letter. [Last accessed on 2007 Jan 30]. Available from: http://www.gene.com/gene/products/ information/pdf/ healthcare-provider-letter.pdf.
27. Brown DM, Kaiser PK, Michels M; Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
28. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
29. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42.